$RCUS News
Last published 1w ago
- 1w agoRCUSArcus Biosciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today
- 2w agoRCUSArcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the
- 3w agoRCUSKuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. (NYSE: RCUS) breached their fiduciary duties
- 3w agoRCUSArcus Biosciences Announces Commencement of Public Offering of Common StockBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today
- 3w agoRCUSArcus Biosciences Investor Event - ARCUS BIOSCIENCES INCEarnings Call TranscriptsAll right. Good morning. Welcome, everybody, to our Castatapen Investor Day. We will be sharing some exciting new data across first, second, and late-line kidney cancer. Before we begin, I'd like to remind you we'll be m
- 3w agoRCUSARCUS BIOSCIENCES - ARCUS BIOSCIENCES INCEarnings Call TranscriptsAll right. Good morning. Welcome, everybody, to our Castatapen Investor Day. We will be sharing some exciting new data across first, second, and late-line kidney cancer. Before we begin, I'd like to remind you we'll be m
- 3w agoRCUSArcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney CancerBusiness WireProgression-free survival (PFS) for casdatifan plus anti-PD-1 in the first-line (1L) setting exceeded third-party benchmarks* for the approved anti-PD-1 plus anti-CTLA-4 regimen (ipilimumab plus nivolumab) and is
- 1mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases,
- 1mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases,
- 1mo agoRCUSArcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of TherapyBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases,
- 1mo agoRCUSMorgan Stanley 24th Annual Global Healthcare Conference - ARCUS BIOSCIENCES INCEarnings Call TranscriptsAll right. Thanks for joining us, everybody. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com back
- 2mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 2mo agoRCUSArcus Biosciences to Participate in Three Upcoming Investor ConferencesBusiness WireArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 2mo agoRCUSKuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. (NYSE: RCUS)...
- 3mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 3mo agoRCUSArcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline UpdateBusiness WireArcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including three new clinical trial collaborations that advance
- 3mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 3mo agoRCUSArcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer PatientsBusiness WireThis agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor
- 3mo agoSMMTRCUSArcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney CancerBusiness WireData Expected to Be Generated by Mid-2027 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people
- 3mo agoRCUSSMMTArcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney CancerBusiness WireData Expected to Be Generated by Mid-2027 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people
- 3mo agoRCUSArcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline UpdatesBusiness WireArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune
- 4mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 4mo agoRCUSNew Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with CasdatifanBusiness WireThis is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biology HIF-2a inhibition with casdatifan
- 4mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 5mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 5mo agoBMYRCUSArcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney CancerBusiness WireThis collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage,
- 5mo agoRCUSArcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune
- 6mo agoRCUSArcus Biosciences First Quarter 2026 Business Updates and Financial Results - ARCUS BIOSCIENCES INCEarnings Call TranscriptsHello everyone. Thank you for joining us and welcome to the ARCIS Biosciences first quarter 2026 business updates and financial results. After today's prepared remarks we will host a question and answer session. Please l
- 6mo agoRCUSArcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline UpdateBusiness WireArcus outlines development strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including the potential to become the first HIF-2a
- 6mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 6mo agoRCUSArcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline UpdatesBusiness WireArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune
- 7mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 7mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 8mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune
- 8mo agoRCUSLEERINK GLOBAL HEALTHCARE CONFERENCE - ARCUS BIOSCIENCES INCEarnings Call Transcriptsmorning everyone my name is Dana Graybosh I'm a senior equity research analyst here at Lyrinc and I'm happy to be joined by Arcus for 30 minutes and we were just commenting there's no way any of us on the stage if you kn
- 8mo agoRCUSArcus Biosciences to Participate in Two Upcoming Investor ConferencesBusiness WireArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune
- 8mo agoRCUSArcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline UpdateBusiness WireUpdated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort At
- 8mo agoRCUSArcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney CancerBusiness WireMedian progression-free survival (mPFS) was 15.1 months, and the confirmed overall response rate (cORR) increased to 45% for the 100mg QD (once daily) tablet cohort in an updated analysis of the ARC-20 study In a
- 9mo agoRCUSArcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline UpdatesBusiness WireArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune
- 10mo agoRCUSArcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation ProgramsBusiness WireArcus's highest priority is to execute on its ongoing Phase 3 trial and overall development plan aimed at establishing casdatifan as the standard-of-care and backbone therapy for clear cell renal cell carcinoma
- 10mo agoRCUSArcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases,
- 11mo agoRCUSArcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology PortfolioBusiness WireThe Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for casdatifan, a
- 11mo agoRCUSArcus Biosciences Announces New Employment Inducement GrantsBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, inflammatory and autoimmune
- 11mo agoRCUSArcus Biosciences to Participate in Two Upcoming Investor ConferencesBusiness WireArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases,
- 1y agoRCUSArcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune
- 1y agoRCUSArcus Biosciences Announces Commencement of Public Offering of Common StockBusiness WireArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune
- 1y agoRCUSArcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline UpdateBusiness WireCasdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney
- 1y agoRCUSTaiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in AsiaBusiness WireTaiho Pharmaceutical Co., Ltd. ("Taiho") and Arcus Biosciences, Inc. (NYSE:RCUS, "Arcus")) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary
- 1y agoRCUSAnti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric StudyBusiness WireFirst overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing